ESCRS - POCAT363 - 1-Year Clinical Outcomes Following Implantation Of An Extended Depth Of Focus Intraocular Lenses

1-Year Clinical Outcomes Following Implantation Of An Extended Depth Of Focus Intraocular Lenses

Published 2026 - 44th Congress of the ESCRS

Reference: POCAT363 | Type: Free paper | DOI: 10.82333/gnv9-fh71

Authors: Dr Joonhyoung Kim* 1 , A/Prof. Jisang Han 2 , A/Prof. Dong Hui Lim 3

1Ophthalmology,Samsung Medical Center ,Seoul,Korea, Republic Of, 2Ophthalmology,Kangbuk Samsung Hospital ,Seoul,Korea, Republic Of, 3Ophthalmology,Samsung Medical Center ,Seoul,Korea, Republic Of;Samsung Advanced Institute for Health Sciences and Technology,Sungkyunkwan University,Seoul,Korea, Republic Of

Purpose

To evaluate the 1-year clinical outcomes of the Tecnis® PureSee extended depth of focus (EDOF) intraocular lens and to assess its visual performance in comparison with the AcrySof® IQ Vivity intraocular lens.

Setting

This retrospective comparative study was conducted at Samsung Medical Center, a tertiary referral hospital in Seoul, South Korea. All surgeries were performed by experienced surgeons using a standardized surgical technique.

Methods

Patients who underwent cataract surgery with implantation of either Tecnis® PureSee or AcrySof® IQ Vivity EDOF intraocular lenses were included. Preoperative and postoperative examinations at 1, 3, 6, and 12 months included uncorrected and corrected distance visual acuity (UDVA and CDVA), manifest refraction, and refractive accuracy. Monocular uncorrected intermediate and near visual acuity were measured at 80 cm, 60 cm, 40 cm, and 33 cm. Defocus curves and contrast sensitivity tests were performed to evaluate functional visual performance. Patient-reported outcomes including spectacle dependence, incidence of dysphotopsia, and overall satisfaction were assessed using standardized questionnaires.

Results

A total of 65 eyes were included, with 25 eyes in the PureSee group and 40 eyes in the Vivity group. In the PureSee group, mean UDVA improved from 0.53 logMAR preoperatively to 0.07 logMAR at 12 months, and CDVA from 0.17 to 0.03 logMAR. At 12 months, UDVA and CDVA showed no significant differences between groups (p=0.642 and p=0.788). Intermediate visual acuity at 80 and 60 cm was comparable between groups. Defocus curve performance did not differ significantly at the original refractive target (approximately −0.25 D). With an additional −0.50 D myopic shift in PureSee, near visual acuity improved versus Vivity while maintaining intermediate vision. No significant differences were observed in dysphotopsia or satisfaction.

Conclusions

The Tecnis® PureSee EDOF intraocular lens demonstrated stable and favorable visual outcomes over a 1-year follow-up period. Compared with the AcrySof® IQ Vivity intraocular lens, PureSee provided comparable distance and intermediate vision. Applying an additional -0.50 D myopic shift improved near visual performance while maintaining comparable intermediate vision, supporting the clinical use of a PureSee mini-monovision strategy.